Intel’s chip manufacturing technology issues are a big problem, according to Goldman Sachs.

The firm lowered its rating to sell from neutral for Intel shares, citing its repeated delays in moving to its next generation chip process technology.

“We see Intel’s struggles with 10nm process technology having ramifications in terms of its competitive position – across a broad set of products,” analyst Toshiya Hari said in a note to clients Friday. “While the 10nm push is well-publicized at this point, we believe Intel’s manufacturing issues could potentially be deeper-rooted than what most think and could have a sustained impact on market share and/or spending levels as Intel competes with a growing/stronger TSMC eco-system.”

Intel shares are down 2.3 percent in Friday’s premarket session after the report. Its stock is up 8.6 percent this year through Thursday versus the S&P 500’s 6.7 percent return.

Hari lowered his price target for Intel shares to $44 from $49, representing 12 percent downside to Thursday’s close.

The analyst noted the company’s repeated delays in moving to the 10 nanometer chip process. Intel said last month that its 10 nanometer chips will be released for holiday 2019 compared with AMD’s 7 nanonmeter products’ launch later this year.

One nanometer equals one-billionth of a meter. Smaller nanometer chipmaking technologies historically have allowed companies to create faster, more power-efficient chips.

“Note any slowdown in the Enterprise spending environment (although this is not our base case view) would also add to the earnings decline we forecast in 2019,” he said.

Intel did not immediately respond to a request for comment.

Products You May Like

Articles You May Like

The walking robot that could soon be delivering your packages
Want to invest like Warren Buffett? Here are the ins and outs of buying preferred stock
JP Morgan warns 3M’s troubles will continue, may cut dividend ‘after 37 straight years of increase’
We need to resolve ethics of CRISPR technology as China awaits third genetically modified baby
Cramer Remix: Investors should take cannabis hype with a grain of salt

Leave a Reply

Your email address will not be published. Required fields are marked *